HCC1954

 

Rincon Bio performs HCC1954 xenograft models to test efficacy of preclinical therapies.  Please see below for additional information or to request a quote. 

Breast

HCC1954 was derived from a primary stage IIA, grade 3 invasive ductal carcinoma with no lymph node metastases.

The HCC1954 is a poorly differentiated cell line initiated on October 30, 1995; it took about 4 months to establish. Ref

Notes

HCC1954 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR).

Her2/neu is overexpressed in the ELISA assay. Ref

in vivo

Forms tumors in nude mice

Used in xenografts to test the efficacy of novel cancer therapeutics 

Request Quote

Receive a quote within one business day for an HCC1954 xenograft

Rincon Bio Growth Curves

HCC1954 1.png

Cell Line: HCC1954

Mouse Strain: Nude from Envigo

Gender: Female

Positive Control: Kadcyla

Concentration: 0.1, 0.33, 0.5, 1, 3.3, 5.5mg/kg

Matrigel: Yes

Dosing: Tail Vein, 1 time

From implant to stratification: 27 days

Cells Implanted per Animal: 5 million

HCC1954 2.png

Cell Line: HCC1954

Mouse Strain: Nude from Envigo

Gender: Female

Positive Control: Kadcyla

Concentration: 2.5, 5 kg/mg

Matrigel: Yes

Dosing: Tail Vein, 1 time

From implant to stratification: 24 days

Cells Implanted per Animal: 5 million

WHY WORK WITH

RINCON BIO?

DOMESTIC QUALITY at COMPETITIVE PRICES

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

PERSONAL TOUCH

 

We love our clients!  We are easy to work with.  And we take a personal interest in our clients and their studies.